ASH: Novartis’s Ianalumab Has Disease-Modifying Potential In ITP
Novartis presented Phase III results for anti-BAFF/ADCC antibody ianalumab in the second-line treatment of immune thrombocytopenia but will wait for first-line data to file for approvals in 2027.
Scrip - December 9, 2025

Pfizer Follows $10bn Metsera Purchase By Licensing YaoPharma Obesity Asset
With its M&A war chest diminished and still seeking to add to its weight-management pipeline, Pfizer obtains an oral GLP-1 analog from Fosun subsidiary YaoPharma.
Scrip - December 9, 2025

BioNTech And Bristol’s Pumitamig Is Encouraging In Triple-Negative Breast Cancer
Interim Phase II data in TNBC is promising for the competitive class of medicines targeting PD-L1 and VEGF.
Scrip - December 9, 2025

Wave Surges As Obesity Candidate Cuts Fat And Spares Muscle
WVE-007 could be a "powerful disruptor" to the existing obesity market, says the company, which is set to raise $250m to fund its Phase II studies.
Scrip - December 9, 2025

Kymera Keeps Rising With More Positive Dupixent-In-A-Pill Data
Early atopic dermatitis data on the oral STAT6 degrader helps the US firm’s hopes of matching the Sanofi and Regeneron injectable blockbuster on efficacy.
Scrip - December 9, 2025

ASH: Kelonia Presents Early Data Giving Boost To In Vivo CAR-T
The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.
Scrip - December 9, 2025

Stock Watch: Just One Reason Not To Invest
An investment only becomes appealing when all the ducks are in a row; if just one duck strays, investors can sense trouble and may hesitate before proceeding.
Scrip - December 9, 2025

ASH: Lilly’s Jaypirca Looks Headed For The Front Line
Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.
Scrip - December 9, 2025

ASH: InnoCare Upbeat About BCL2 Inhibitor Mesutoclax In MCL
InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.
Scrip - December 9, 2025

Xeltis Raises €50M To Advance Tissue-Regenerating Dialysis Access As CMS Opens Door To New Options
Xeltis secured €50m to scale and market its aXess vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. With EU regulatory review underway and US trials advancing, Xeltis sees new US Medicare rules as a major opening for alternative treatments.
Medtech Insight - December 10, 2025

NAD Closes Case After Tooth Whitening Marketer Discontinues All Challenged Claims
St. Petersburg, Fla.-based Smile&Shine Essentials, Inc. said it had discontinued all express and implied claims at issue in a NAD case over its InoPro Whitening Strips brought forward by Beverly Hills-based challenger Oral Essentials, Inc., a regular participant in the self-regulatory forum.
HBW Insight - December 9, 2025

People On The Move: Appointments At Stada, Nestlé, CMA
A round-up of the latest people moves: Stada names general counsel; Nestlé announces departures; CMA elects board members.
HBW Insight - December 9, 2025

Potential US Exit From USMCA Would Place $10.1Bn Cosmetics Sector At Risk – PCPC
The North American cosmetics sector would face major supply-chain and regulatory risks if USMCA is not renewed, says PCPC, which encouraged the US Trade Representative during a Dec. 5 hearing to keep the agreement and its Cosmetics Annex in place as it prepares its Jan. 2 recommendation to Congress.
HBW Insight - December 9, 2025

AAM Urges ‘Steady Leadership’ At FDA Following Pazdur’s Abrupt Resignation
With Richard Pazdur’s abrupt exit marking the fifth CDER leadership change in a year, the AAM is urging continuity and stability amid the ongoing turbulence.
Generics Bulletin - December 9, 2025

Belgian Regulator Presses Roche Further Over Biosimilar Abuse Allegations
The Belgian Competition Authority has confirmed that it is escalating a complaint against Roche over alleged strategies used to delay biosimilar competition to rituximab and trastuzumab.
Generics Bulletin - December 9, 2025

Hopewell Told Delay Is ‘Of Its Own Making’ As Cladribine Stay-Lifting Bid Fails
Delaware district court refuses to shorten 30-month stay, leaving Hopewell unable to launch its generic Mavenclad product.
Generics Bulletin - December 9, 2025

Biocon-BBL Integration: Can It Unmask The Biosimilars Arm’s Intrinsic Worth?
The consolidation of Biocon-BBL is expected to unlock value, deliver operational synergies and provides BBL’s minority shareholders an 'earlier liquidity event'. Investor Viatris also signals accelerated expiration of biosimilars non-compete restrictions.
Generics Bulletin - December 9, 2025

Wherever Medtech Goes, AI Will Have One Hand On The Steering Wheel
The rise and fall of US tariffs and the chill headwind from China’s state procurement policies have blown onto medtech’s radar. But how to monetize AI is the dominant concern up and down the industry.
In Vivo - December 8, 2025

Biopharma In 2026: From Darwinian Reset To Disciplined Growth
The biopharmaceutical landscape in 2026 will be shaped by rapid technological progress, shifting geographic leadership, a looming patent cliff and a renewed focus on capital efficiency.
In Vivo - December 8, 2025

As Lilly And Novo Nordisk Grow Their Obesity Empires, What Comes Next?
Beyond the fierce Lilly and Novo Nordisk competition in the weight-management market, other deep-pocketed firms are advancing their novel candidates and seeking a way in through dealmaking.
In Vivo - December 8, 2025